ORION Biotech Catalyst Calendar
Menu

CRBP · Clinical results disclosure

CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data

  1. “Q1 2027” · SEC Exhibit 99.2
  2. “Q1 2027” · SEC Exhibit 99.1 and Company press release

Said “Q1 2027” on Aug 6, 2026; still “Q1 2027” on Sep 14, 2026; no results filing found as of Sep 14, 2026.

Corbus Pharmaceuticals (CRBP) · Record A20-CRBP-701-1L-COMBO

Details

Corbus Pharmaceuticals (CRBP) stated CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data: “Q1 2027” (SEC Exhibit 99.1, filed ); the most recent dated timing wording located () was “Q1 2027” (SEC Exhibit 99.2 · ).

Reviewed status as of : Company’s stated window: still open.

When did Corbus Pharmaceuticals say CRB-701 + pembrolizumab results would come?

On , Corbus Pharmaceuticals wrote in its SEC Form 8-K: “Report CRB-701 + pembrolizumab data in 1L — Q1 2027” (Source)

Days left in the window the company stated: 163 · company’s wording: “Q1 2027”

Timeline card: CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data, latest timing wording as written, with dates and documents
Download card

Wording before and after

Before ·

Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027

Timing wording: “Q1 2027” · SEC Exhibit 99.1 · SEC original

Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027

Timing wording: “Q1 2027” · Company press release · Company original

After ·

Report CRB-701 + pembrolizumab data in 1L — Q1 2027

Timing wording: “Q1 2027” · SEC Exhibit 99.2 · Company-hosted SEC exhibit

Watch this program: confirm your email to start one daily alert digest.

Or email ORION to ask for this Watch.

First stated window
“Q1 2027”SEC Exhibit 99.1, filed
Disclosure date
None foundLast checked:

Timeline

How wording is compared

Equivalent half-year, quarter, and year notations are compared together while original wording stays visible. Qualifiers such as early, mid, late, and end remain distinct. A slash and or are compared together for two complete timing alternatives with explicit years. Each source is compared with the preceding checked date. Different wording in documents from the same day is shown separately, without assigning an order within that day. No comparison is made against a preceding date with different timing expressions. Status is set by founder review of the original filings.

DocumentDateEvent retainedExact company wordingReviewSource
SEC Exhibit 99.1Initial entry within checked sources: “Q1 2027”Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027Checked by founderSEC original
Company press releaseStatement retained: “Q1 2027”Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027Checked by founderCompany original
SEC Exhibit 99.2Statement retained: “Q1 2027”Report CRB-701 + pembrolizumab data in 1L — Q1 2027Checked by founderCompany-hosted SEC exhibit

Sources

Last checked: . Compared by hand with the original filings by Jiwoo Seong (Woo).

Corrections

No corrections yet (as of ).

A correction is added here with its date, what changed, why, and the evidence. The earlier version is not deleted. Report an error: hello@orionbiotechai.com. If you want your name shown with the correction, include it; otherwise no name is shown.

Program file

Name as filed
CRB-701 + pembrolizumab
Other names in filings
None listed
Indication in the filing
1L OPSCC
Trials named in the same filing
None listed
Latest timing wording
“Report CRB-701 + pembrolizumab data in 1L — Q1 2027”
Source
8-K · filed · SEC accepted · accession 0001193125-26-389829 · SEC original
Review
Checked by founder against the original filing
Last checked

Program CRBP-crb-701-pembrolizumab.

Corbus Pharmaceuticals (CRBP) — CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data: “Q1 2027” (SEC Exhibit 99.1 2026-08-06); statement retained “Q1 2027” (2026-08-06); statement retained “Q1 2027” (2026-09-14). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-ex99_1.htm | https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update | https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-389829/crbp-ex99_2.htm

Terms

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology. Status definitions.